These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus. Chiricozzi A; Garcovich S; Malvaso D; Giovanardi G; Peris K Int J Dermatol; 2020 Nov; 59(11):1423-1424. PubMed ID: 32966593 [No Abstract] [Full Text] [Related]
27. Long-term secukinumab efficacy in patients with moderate to severe hidradenitis suppurativa: A retrospective single-centre case series (23 patients). Melgosa Ramos FJ; García Ruiz R; Estébanez Corrales A; Mateu Puchades A J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):e517-e519. PubMed ID: 36268711 [No Abstract] [Full Text] [Related]
28. Secondary gastrointestinal amyloid A amyloidosis possibly caused by hidradenitis suppurativa. Kochi S; Esaki M; Kurahara K Dig Endosc; 2018 Sep; 30(5):681. PubMed ID: 29933503 [No Abstract] [Full Text] [Related]
29. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa. Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051 [TBL] [Abstract][Full Text] [Related]
30. Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab. Nikolakis G; Kreibich K; Vaiopoulos A; Kaleta K; Talas J; Becker M; Zouboulis CC F1000Res; 2021; 10():381. PubMed ID: 34540202 [TBL] [Abstract][Full Text] [Related]
31. Hidradenitis suppurativa managed with adalimumab. Yamauchi PS; Mau N J Drugs Dermatol; 2009 Feb; 8(2):181-3. PubMed ID: 19213236 [TBL] [Abstract][Full Text] [Related]
32. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429 [TBL] [Abstract][Full Text] [Related]
33. Association of hidradenitis suppurativa and familial Mediterranean fever: A case series of 6 patients. Abbara S; Georgin-Lavialle S; Stankovic Stojanovic K; Bachmeyer C; Senet P; Buob D; Audia S; Delcey V; Fellahi S; Bastard JP; Awad F; Legendre M; Amselem S; Grateau G Joint Bone Spine; 2017 Mar; 84(2):159-162. PubMed ID: 27238193 [TBL] [Abstract][Full Text] [Related]
34. Interstitial keratitis secondary to severe hidradenitis suppurativa: a case report and literature review. Alzaga Fernandez AG; Demirci H; Darnley-Fisch DA; Steen DW Cornea; 2010 Oct; 29(10):1189-91. PubMed ID: 20628295 [TBL] [Abstract][Full Text] [Related]
35. Delayed drug hypersensitivity reaction to secukinumab in a patient with hidradenitis suppurativa. Konda S; Shetty N; Friedman B; Veenstra J BMJ Case Rep; 2022 May; 15(5):. PubMed ID: 35580946 [TBL] [Abstract][Full Text] [Related]
36. Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases). Reguiaï Z; Fougerousse AC; Maccari F; Bécherel PA J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):e750-e751. PubMed ID: 32401354 [No Abstract] [Full Text] [Related]
37. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial. Casseres RG; Prussick L; Zancanaro P; Rothstein B; Joshipura D; Saraiya A; Turkowski Y; Au SC; Alomran A; Abdat R; Abudu M; Kachuk C; Dumont N; Gottlieb AB; Rosmarin D J Am Acad Dermatol; 2020 Jun; 82(6):1524-1526. PubMed ID: 32044410 [No Abstract] [Full Text] [Related]
38. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report. Thorlacius L; Theut Riis P; Jemec GBE Br J Dermatol; 2018 Jul; 179(1):182-185. PubMed ID: 28654150 [TBL] [Abstract][Full Text] [Related]
39. Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities. Crowley JJ; Mekkes JR; Zouboulis CC; Scheinfeld N; Kimball A; Sundaram M; Gu Y; Okun MM; Kerdel F Br J Dermatol; 2014 Dec; 171(6):1561-5. PubMed ID: 24842009 [No Abstract] [Full Text] [Related]
40. New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa. Molinelli E; Gioacchini H; Sapigni C; Diotallevi F; Brisigotti V; Rizzetto G; Offidani A; Simonetti O Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176138 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]